Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Replicel Life Sciences Inc V.RP

Alternate Symbol(s):  REPCF

RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCS-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells, a type of fibroblast cell isolated from the hair follicle to repair and regenerate tissue. RCT-01 provides a source of collagen expressing cells to the site of injury, addressing the underlying cause of tendinosis. It has also developed an injection device, DermaPrecise, which improves the administration of its cell therapy products and certain other injectables.


TSXV:RP - Post by User

Post by Ingiboyon Jun 21, 2022 11:31am
207 Views
Post# 34771329

Private Placement

Private PlacementFrom Stockwatch June 7th:
"On May 4, 2022, the company closed a first tranche of the offering pursuant to which it sold an aggregate of 4,218,470 units for gross proceeds of $759,324.60."


From Stockwatch May 28th:
"Mr. Schutte is a director of the company. On May 4, 2022, the acquiror acquired 2,102,303 units from the company on a private placement."

I wonder who bought the other 2,116,167 ?  

The original total offered was 8,333,333.  That is an additional 4,114,863 to be sold.....I wonder how it is going ?

From Stockwatch may 28th:
"outstanding shares as of May 4, 2022, based on the aggregate of 45,021,496 shares, consisting of: (i) 42,749,565 shares outstanding as of May 4, 2022; (ii) 303,030 shares that may be issuable on conversion of Class A preference shares; (iii) 355,000 shares that may be issuable on exercise of options; and (iv) 1,613,901 shares that may be issuable on exercise of warrants."


The current market capitalization @ $.12 is $5,402,579 .  This is ripe for a hostel takeover !



 

 


<< Previous
Bullboard Posts
Next >>